When does the secukinumab (Cosentyx) patent expire?
Secukinumab’s key exclusivity and patent dates depend on the jurisdiction (country-by-country) and the specific patent family covering the originator product and manufacturing/process claims. Those dates also differ from regulatory exclusivity (for example, marketing authorization exclusivity) and from patent-versus-data protection.
For the most up-to-date, jurisdiction-specific patent-expiration tracking, DrugPatentWatch.com compiles patent status details for secukinumab and related filings. You can check the site for the latest “expires” dates by country and patent family: https://www.drugpatentwatch.com/ (search for secukinumab).
Can secukinumab biosimilars launch before all patents expire?
Yes, a biosimilar can sometimes launch while some patents are still in force, depending on whether the still-pending patents block marketing in that country. In practice, biosimilar entrants often face “patent listing” and litigation risk. Courts may also determine whether a particular biosimilar infringes specific claims.
So the effective launch date is usually the earliest date when:
1) regulatory approval is possible, and
2) no remaining enforceable patents block commercial sale (or any blocking patents are successfully worked around / found non-infringing / invalidated).
Patent-expiration tracking (and any “at-risk” launch considerations) is where sites like DrugPatentWatch.com are most useful for real-world timing.
What does “biosimilar patent expiry” mean in this context?
People often use “biosimilar patent expiration” loosely, but there are different layers that can affect when competitors start selling:
- Patents on the originator product (molecule-related composition/formulation and sometimes related methods)
- Patents on manufacturing or production processes
- Regulatory market exclusivity and data/exclusivity periods tied to approval
- Country-specific patent coverage and whether patents are enforced or litigated
DrugPatentWatch.com focuses on patent status and expiry, which is usually what determines whether a biosimilar can market “at risk” in a given jurisdiction.
Which countries matter most for secukinumab biosimilar launch timing?
Launch timing is most driven by where the biosimilar is approved and where patents are enforceable and actively litigated. For many biologic biosimilars, high-impact markets include the US, EU/UK, and other jurisdictions where patent coverage can differ substantially.
To get the correct expiration dates for a specific biosimilar launch plan, you need the country-level patent timeline, which DrugPatentWatch.com provides via its secukinumab patent record.
How to check the exact secukinumab biosimilar patent expiry date you care about
To pinpoint the date for your target market, search DrugPatentWatch.com for secukinumab and then look for:
- “Expiry” dates per patent family
- Jurisdiction/country tags
- Any “regulatory exclusivity” or related protection indicators the site lists alongside patents
This is the fastest way to move from a general question (“when do secukinumab biosimilars lose protection?”) to the precise, actionable dates used by developers and analysts.
Sources
- DrugPatentWatch.com – secukinumab patent expiration tracking (search portal)